AUS
NZ
UK
CA
USA
IND
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This groundbreaking approval not only signifies a major advancement in neuropsychiatric care but also triggers $29 million in milestone payments for PureTech under agreements with Royalty Pharma and Karuna Therapeutics, the latter of which was acquired by Bristol Myers Squibb (NYSE:BMY) earlier this year.
Cobenfy is the result of PureTech’s innovative approach to drug development, where it combined two biologically active molecules—xanomeline and trospium chloride. This strategic combination was aimed at overcoming tolerability challenges that have historically impeded the progress of similar treatments. By founding Karuna Therapeutics, PureTech advanced this promising drug, which has now reached the market under the stewardship of BMS.
Dr. Eric Elenko, Co-founder and President of PureTech, remarked, “The FDA approval of Cobenfy is a significant milestone in our mission to transform the lives of patients with devastating diseases.” He noted that the successful validation of their initial hypothesis around tolerability issues has led to a major breakthrough for individuals living with schizophrenia. “I am equally pleased that our unique approach to R&D has delivered yet another novel therapeutic to patients,” he added.
The FDA’s approval is not only a victory for patients but also for PureTech’s financial model. The agreements associated with Cobenfy include future milestone payments and approximately 2% royalties on net annual sales exceeding $2 billion. To date, PureTech has generated approximately $1.1 billion, primarily through monetization strategies involving its equity stakes in Karuna and strategic partnerships, including the recent acquisition by BMS.
Dr. Bharatt Chowrira, CEO of PureTech, emphasized the significance of this achievement. “The FDA approval of Cobenfy is a testament to our unique R&D engine, which has now produced three FDA-approved therapeutics,” he stated. The company’s innovative model, which allows it to self-fund multiple programs, is a key driver of its growth strategy.
Cobenfy represents a significant advancement in the treatment landscape for schizophrenia, providing patients with a novel option that addresses both efficacy and tolerability. Schizophrenia affects millions of individuals worldwide, and the introduction of new therapies like Cobenfy can enhance treatment options and improve quality of life.
PureTech's ability to navigate the complexities of drug development while focusing on high-impact therapeutic areas underscores its commitment to patient care. The company’s successful initiatives in developing Cobenfy reflect its broader mission to change lives through innovative biotherapeutics.
With the launch of Cobenfy and the ongoing success of its other therapeutic programs, including LYT-100 and LYT-200, PureTech is poised for further advancements in biopharmaceutical innovation. The company plans to leverage its unique development model as it explores new opportunities within its pipeline and through partnerships.
In summary, PureTech Health's recent FDA approval of Cobenfy marks a pivotal moment in the treatment of schizophrenia and exemplifies the company's commitment to addressing significant medical needs through innovative solutions. As PureTech continues to evolve, its focus on groundbreaking therapies promises to benefit countless patients facing challenging health conditions.
